Cost-Effectiveness Analysis of Pembrolizumab for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Taiwan

  • Wen, Yu-Wen (PI)
  • Chao, Yin-Kai (CoPI)
  • Liao, Chun Ta (CoPI)

Project: National Science and Technology CouncilNational Science and Technology Council Academic Grants

Project Details

Abstract

在國家層面來說,將適當的治療應用於適當的病人,使得醫療資源能夠充分利用,對於台灣社會 效益能夠達到最大,進而能夠提出相對應醫療政策已降低國家的醫療資源配置不均或浪費。 就學術研究而言,本計畫在復發或轉移頭頸部鱗狀細胞癌病患的免疫療法治療上提供其成本效益分析的結果,而且其結果應可發表文章於國際期刊上,並提供給政府醫療相關部門在政策制定及規劃之參考。對病患而言,在能夠兼具成本考量下,接受具有成本效益的治療。

Project IDs

Project ID:PF11307-2568
External Project ID:NSTC113-2410-H182-005
StatusActive
Effective start/end date01/08/2431/07/25

Keywords

  • Pembrolizumab
  • Cost-effectiveness analysis
  • Head and neck cancer
  • Squamous cell carcinoma

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.